Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
Jeffrey A. Jones(The Ohio State University), Anthony R. Mato(University of Pennsylvania), William G. Wierda(The University of Texas MD Anderson Cancer Center), Matthew S. Davids(Dana-Farber Cancer Institute), Michael Y. Choi(UC San Diego Health System), Bruce D. Cheson(Georgetown University), Richard R. Furman(Cornell University), Nicole Lamanna(Columbia University Irving Medical Center), Paul M. Barr(University of Rochester Medical Center), Lang Zhou(AbbVie (United States)), Brenda Chyla(AbbVie (United States)), Ahmed Hamed Salem(AbbVie (United States)), Maria Verdugo(AbbVie (United States)), Rod Humerickhouse(AbbVie (United States)), Jalaja Potluri(AbbVie (United States)), Steven Coutré(Stanford University), Jennifer A. Woyach(The Ohio State University), John C. Byrd(American Association of Colleges of Pharmacy)
Cited by 377Open Access
Abstract
Related Papers
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts, Matthew S. Davids, John M. Pagel et al.|New England Journal of Medicine|2015|1.9k